Medicometrics

Independent analysis of pharmaceuticals and healthcare data through publicly available information.

Tag: Medicare Part D

  • Medicare Part D Biologics and Biosimilars Analysis (2019-2023)

    Biologics are drugs produced from living organisms or containing specific components derived from living organisms. Biosimilars are products similar to biologics in efficacy, composition, and mechanism of action. Biosimilars are considered derivatives of biologics. They are manufactured after the reference product’s (Biologic) patent license expires.

    In this post, we will examine multiple biologics and analyze spending trends for the biosimilars in Medicare Part D. Our primary focus is overall spending, claims trends, and cost per prescription from 2019 to 2023.

    READ MORE

  • Oncology Drugs Spending Trend in Medicare Part D (2019-2023)

    Oncology drugs account for a major share of total Medicare Part D spending due to their high cost. In this blog post, we will perform an exploratory analysis of this critical drug class and its contribution to the Medicare drug coverage program.

    (more…)

  • Evolution of Anticoagulants in Medicare Part D (2019-2023)

    Anticoagulants constitute a significant portion of Medicare Part D spending. Previously, we looked into the contribution of anti-diabetics to the Medicare drug coverage program. In this post, we will explore the role of anticoagulants in Medicare Part D spending (2019-2023).

    (more…)

  • The Rise of GLP-1 Drugs in Medicare Part D (2019-2023)

    The previous analysis revealed that a large portion of Medicare Part D spending was concentrated in a small number of drugs. Among all drug classes, GLP-1 agonists emerged as a clear winner. In this post, we will examine the contribution of GLP-1 drugs to Medicare Part D spending over the years (2019-2023).

    (more…)